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Intrauterine growth retardation (IUGR) is one of between the frontal lateral margin to the pos-
the most important fetal complications in peri-
natology. With the recent advances in ultrasonic
measurements, the early recognition of fetal
maldevelopment has become possible.
In a prospective study of pregnancies with a fetal
body weight ultrsonographically determined to be
less than the 10th percentile of population, pre-
natal treatment consisting of daytime bedrest,
high protein diet and oral administration of
allylestrenol was assessed.
1 Material and Methods
A total of 30 pregnancies was investigated. In
these pregnancies, the intrauterine gestational
age was confirmed in the frist trimester of preg-
nancy by routine ultrasonic measurements of
crown-rump length (CRL), using the standard of
ROBINSON [5]. Both biparietal diameter (BPD)
and abdominal circumference (AC) were measured
in the third trimester. An ultrasonograph (^loka,
SSD-256) with a 3.5 MHz transducer was used
in both the first and third trimester measure-
ments. The ultrasound tissue velocity used was
1,540 meters per second. CRL was measured with
electronic calipers when the fetal echo complex
was shown at its maximum length. BPD scan was
obtained when the cranium became oval at an
angle so that the clear midline structure and the
lateral ventricles could be observed. The distance
terior internal margin of the cranium was meas-
ured with electronic calipers. A photograph
was made when the umbilical vein could be
observed in a transverse scan at the right angle
Fig. 1. Biparietal diameter (BPD) and abdominal circum-
ference (AC).
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to the long axis of the fetus, and the AC was
measured by a map reader (Uchida) (Fig. 1).
Then, the fetal weight was estimated from the
BPD and AC measurements in accordance with the
method of WARSOF et al. [14] and SHEPARD et al.
[8], using an equation of Iog10 (body weight)
= - 1.599 + 0.144 (BPD) + 0.032 (AC) - 0.111
(BPD2 χ AC)/1,000 (equation I) and an equation
of Iog10 (body weight) = - 1.7492 + 0.166 (BPD)
+ 0.046 (AC) - 2.646 (AC χ BPD)/1,000 (equa-
tion II). In those 30 pregnancies, each the estimated
fetal body weight was less than lOthpercentile of
the intrauterine growth curve of NlSHlDA [4] for
the Japanese at more than two ultrasonic measure-
ments separated by two weeks. Maternal bio-
chemical determinations were also performed on
these pregnancies. The plasma unconjugated estriol
value was measured with a CEA-IRE-Sorin RIA
kit. Urinary estriol was determined on an 8-hour
pooled specimen collected at night with a Teizo
colorimetric kit and converted into that of a
24-hour urine. Plasma human placental lactogen
(HPL) was assayed with a Kyorin EIA kit. Plasma
unconjugated progesterone value was measured
with a Daiichi RIA kit. Serum heat-stable alkaline
phosphatase (HSAP) and leucine amino-peptidase
(LAP) were determined colorimetrically. The
patients were treated with daytime bedrest, high
protein diet (2 g/kg/day) and oral administration
of allylestrenol (GESTANON®, NIPPON ORGANON)
in a dose of 30 mg/day until the time of delivery.
Both ultrasonic and biochemical measurements
were repeated weekly. For statistical analysis,
Student's t-test was applied.
2 Results
The calculated values of the various measurements
obtained prior to and following treatments were as
follows.
2.1 Estimated fetal body weight
As shown in Tab. I, the initial gestational age of
the 30 patients who were diagnosed as IUGR after
at least two measurements taken two weeks apart
were an average of 32.9 ± S.D. 2.4 weeks, and
the estimated average fetal body weight was
1,362 ±316 g by equation I and 1,430 ±337 g
by equation II. In the final assessment at
39.2 ± 1.8 weeks' gestation, the estimated average
fetal body weight had increased to 2,678 ± 458 g
by equation I and to 2,787 ± 477 g by equation II.
Therefore, the average weekly gain of estimated
fetal body weight was 223 ± 83 g by equation I
and 219 ± 64 g by equation II, both of which were
statistically significantly (p < 0.01) larger than the
standard weekly increase at the 50th percentile
level of NlSHlDA's intrauterine growth curve [4],
171 ±42g, confirming the efficacy of prenatal
threapy. Intrauterine weight chart of each case is
illustrated on Fig. 2.
2.2 Estimated fetal body weight and actual
birth weight
As stated above, the final estimated fetal body
weight was 2,678 ± 458 g by equation I and
2,787 ± 477 g by equation II, on average, at
39.2 ± 1.8 weeks' gestation, and the actual birth
weight was an average of 2,685 ± 479 g at
39.5 ±1.7 weeks' gestation. Significant correla-
tions (r = 0.94 on both equations) between the
estimated fetal body weight and the actual birth
weight were found, and it was confirmed that
these estimating methods were useful in the
prenatal diagnosis of IUGR. Standard deviations in
birth weight predictions were 178 g in equation I
and 259 g in equation II. With respect to the birth
weight, 14 (46.6%) showed a lower weight than
10th percentile of Nl SHIP A's growth curve [4].
The average placental weight of these cases was
490±95g. The fetal/placental weight ratio was
5.52 ± 0.64 on average, which was somewhat
lower than that of normal pregnancy (usually,
between 5.9 and 6.3). Fetal distress was not
encountered in any of these cases during the
course of delivery. All neonates had a one-minute
APGAR Score of more than 8.
2.3 BPD and AC measurements
The BPD and AC measurements taken at 32.9 ± 2.4
weeks' gestation were 76 ± 6 mm and 25 ± 2 cm,
respectively, and those at 39.2 ±1.8 weeks' gesta-
tion were 87 ± 4 mm and 33 ± 2 cm, respectively.
On the basis of SABBAGHA's standard [6], the BPD
was below 10th percentile in 23 cases (76.7%) at
the initial measurement, and in 22 (73.3 %) at the
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Fig. 2. Intrauterine weight chart. Equation I was used in calculation.
final measurement. Similarly, on the basis of
TAMURA'S standard [11], the AC was below
the 10th percentile in 30 (100%) at the initial
measurement, and in 21 (70.0%) at the final
measurement. The average weekly increase of BPD
was 1.8 ± 0.6 mm, which was insignificant to
the standard gain of 1.6 ±0.3 mm according
to SABBAGHA'S values [6] at 50th percentile
level. The average weekly increase of AC was
1.3 ± 0.4 cm, which was a statistically significant
(p<0.01) increase over the standard gain of
1.1 ± 0.2 cm according to TAMURA's value [11] at
50th percentile level.
2.4 Maternal biochemical values
Tab. II demonstrates the maternal plasma üncon-
jugated estriol, urinary estriol, plasma HPL, plasma
unconjugated progesterone, serum HSAP and
serum LAP concentration values at 32.9 ± 2.4
weeks' gestation and the values following three
weeks of prenatal treatment. The initial plasma
unconugated estriol value was 2.9 ± 2.2 ng/ml on
average, and in 20 patients (66.7%) the value was
abnormally low on the basis of TULCHINSKY's
standard [12]. Three weeks after treatment it
was 5.2±3.5ng/ml which was a statistically
significant (p<0.01) increase, but 15 (50.0%)
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Tab. 1. Fetal hiparictal diameter (BPD), abdominal circumference (AC) and































































































































































































































































































































































































































Note) * less than 10th percentile. UPI: utero-placental insufficiency. UTI: urinary tract infection, np: nullipara.
still showed abnormally low values. Likewise, the
urinary estriol value at the initial measurement was
an average of 13.3 ± 6.5 mg/day, and 8 cases
(26.7 %) had abnormally low values on the basis of
BEISCHER's standard [2]. Three weeks after treat-
ment it increased to 23.4 ± 10.2 mg/day which
was a statistically significant (p<0.01) increase,
but only two (6.7%) of the patients had abnor-
mally low values. The plasma HPL value was an
average of 4.8 ± 1.2 Mg/ml at the initial measure-
ment, and on the basis of VARMA's standard [13]
6 (20.0%) showed an abnormally low value.
Three weeks after treatment the average value was
5.9 ±1.6 Mg/ml, which was statistically significant
(p < 0.01) increase in value, but 3 (10.0%) had an
abnormally low value. Initially, the plasma uncon-
jugated progesterone value was 98 ± 26 ng/ml,
but after three weeks' treatment it increased to
121 ±35 ng/ml, which was statistically significant
(p<0.01) increase. The serum HSAP and LAP
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were initially 9.2 ± 7.1 KAU and 395 ± 207 mU/ml,
respectively, and after three weeks' therapy they
increased to 12.7 ± 7.9 KAU and 461 ± 177mU/inl
respectively. Both values increased after treatment,
but the increase was insignificant in either case. On
the basis of YAMAGUCHI's standard [16], the
serum HSAP value was abnormally low in 7
patients (23.3%) initially and in one patient
(3.3 %) after treatment.
3 Discussion
In the diagnosis of IUGR, it is important to con-
firm the gestational age. Since the fetal growth
during the first trimester follows a definite growth
pattern, it would be better to ascertain the gesta-
tional age by routine ultrasonic measurements of
either CRL during 6 to 15 weeks' gestation or BPD
during 10 to 19 weeks' gestation. There are several
ultrasonic methods to estimate the fetal body
weight using BPD, AC, total inrauterine volume
JLPer ina t .Med. i l (1983)
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and so on. WARSOF et al. [14] reported that a
logarithmic equation (equation I in this study)
with use of both BPD and AC had an absolute
mean error of 228 g or 8.0%. Later, SHEPARD
et al. [8] stated that equation I and a new equation
(equation II in this study) had standard deviations
of 212 g and 219 g respectively, when the fetal
body weight was less than 2,500 g. In this study,
the standard deviations of equation I and II were
178 g and 259 g respectively, for birth weight
predictions. Correlation coefficients were 0.94 for
both equations confirming that these equations for
calculation of the estimated fetal body weight
is useful in in the prenatal diagnosis of IUGR.
Having taken these facts into consideration, we
measured and corrected the gestational age of our
IUGR patients in the first trimester, calculated the
estimated fetal body weights from the BPD and
AC measurements during the third trimester, and
selected those patients whose estimated fetal body
weights derived from at least two ultrasonic
measurements separated by two weeks were less
than the 10th percentile of the intrauterine growth
curve of NlSHIDA [4] for the Japanese.
In IUGR, there is fetal hypoplasiä, with a decrease
in both numbers of somatic cells and total DNA
amounts in the tissue; there is also fetal malnutri-
tion, with a decrease in both volume of somatic
cells and protein/DNA ratio in the tissue. With the
former, prenatal treatment is difficult; therefore,
the underlying etiologies should be identified using
antenatal diagnostic measures such as ultrasono-
graphy. For nutritional disorders, daytime bedrest
was indicated to enhance the placental bloodflow,
and high protein diet was encouraged as well.
Allylestrenol has been reported to increase urinary
HCG, pregnandiol, HPL and estriol in pregnant
women [7, 9,10], and it has been reported to have
a placentotrophic, pregnancy-maintaining and
weight-promoting activity in the fetus [7]. Allyl-
estrenol does not have estrogenic, androgenic and
anabolic effects as some of the gestagens [1,3,
15]. Indeed, the administration of allylestrenol
was followed by significant increases of estriol,
HPL and progesterone in this study, although
some of those increments would be attributed to
the increase in gestational age. An attempt to
promote fetal weight without consideration of the
functional status of the placenta is detrimental for
the fetus, since this eventually increases the fetal
volume/oxygen supply ratio. However, following
allylestrenol treatment, the fetal/placental weight
ratio was considerably smaller than that of normal
pregnancy. Other important matters in the pre-
natal management IUGR would be:
1. to properly evaluate the fetal wellbeing and the
intrauterine environment,
2. to determine the exact time of delivery while
preventing both intrauterine fetal death and
iatrogenic prematurity, and
3. to provide an efficient perinatal care to the
newborn infant.
Summary
Prenatal treatment consisting of daytime bedrest, high
protein diet and oral administration of allylestrenol was
assessed in a prospective study of 30 patients with IUGR
infants whose ultrasonically estimated body weight was
less than the 10th percentile. In these pregnancies, the
gestational age was confirmed in the first trimester, and
the fetal weight was estimated from the BPD and AC
measurements in the third trimester (Fig. 1). Following
treatment, ultrasonic and biochemical determinations
were performed. As results:
1. The estimated fetal weight of 1,362 g at 32.9 g gesta-
tional weeks increased to 2,678 g at 39.2 weeks on
average. The average weekly weight gain was significantly
higher than the standard, and 16 cases (53.3%) were
more than 10th percentile at birth (Tab. I, Fig. 2).
2. A significant correlation (r - 0.94) between the
estimated fetal weight and the birth weight was found.
3. Following prenatal treatments, maternal plasma and
urinary estriol, plasma HPL and progesterone increased
significantly (Tab. II).
Keywords: Allylestrenol, estriol, fetus, HPL, HSAP, intrauterine growth retardation, LAP, progesterone, ultrasono-
graphic measurement.
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Zusammenfassung
Piänatale Diagnose und Therapie der intrauterinen Wachs-
tumsretardierung
In einer prosepektiven Studie untersuchten wir die Wirk-
samkeit einer pränatalen Behandlung der intrauterinen
Wachstumsretardierung bei 30 Patientinnen. Die Therapie
bestand in Verordnung von Bettruhe, proteinreicher Diät
und oraler Gabe von Allylöstrenol. Das durch Ultraschall
geschätzte Gewicht der Feten lag unterhalb der 10-er-
Perzentile. Wir bestimmten das Schwangerschaftsalter im
I.Trimester und ermittelten im S.Trimester das fetale
Gewicht durch Messung des biparietalen Durchmessers
und abdominellen Bauchumfangs (Fig. 1). Nach der
Therapie führten wir ultrasonographische und biochemi-
sche Kontrollen durch. Unsere Ergebnisse:
1. Während das Gewicht in der 32,9. Schwangerschafts-
woche bei durchschnittlich 1362g lag, stieg es bis zur
39,2. Woche auf ein mittleres Gewicht von 2678g an.
Die durchschnittliche Gewichtszunahme pro Woche
war signifikant höher als der Standardwert. 16 Kinder
(53,3%) lagen mit ihrem Gewicht zum Zeitpunkt der
Geburt oberhalb der 10-er-Perzentile (Tab. I, Fig. 2).
2. Die Korrelation zwischen geschätztem und tatsäch-
lichen Geburtsgewicht war signifikant (r = 0,94).
3. Nach der pränatalen Therapie zeigten die Östriolwerte
im Plasma und Urin sowie die HPL- und Progesteronwerte
im Plasma einen signifikanten Anstieg (Tab. II).
Schlüsselwörter: Allylöstrenol, Fetus, hitzestabile AP, HPL, intrauterine Wachstumsretardierung, LAP, Östriol, Pro-
gesteron, Ultraschallmessung.
Resume
Diagnostic prenatal et traitements du retard de croissance
intra-uterine
Dans une etude prospective protant sur 30 patientes avec
un enfant ayant un RCIU dont le poids corporel estime
par ultrasons est inferieur au dixieme percentüe, les thera-
peutiques prenatales, a savoir le repos au lit quotidien, le
regime hyperprotidique et la prise orale d'allylestrenol,
ont ete mises ä Tepreuve. Pour ces grossesses, Page gesta-
tionnel a ete confirme au cours du premier trimestre et le
poids fcetal estime au cours du troisieme trimestre par
determination du Bip et de Pabdomen (Fig. 1). A la suite
des mesures therapeutiques, ont ete realises des examens
biochmimiques et echographiques. Les resultats sont les
suivants:
1. Le poids foetal estime de 1362g ä 32,9 semaines de
gestation s'est accru jesqu'ä 2678 g ä 39,2 semaines en
moyenne. Le gain ponderal hebdomadaire moyen a ete
plus eleve de faqon significative que normalement et
16 cas (53,3%) ont eu un poids superieur au lOeme
percentile a la naissance (Tab. I, Fig. 2).
2. Une correlation significative (r = 0,94) a ete mise en
evidence entre Pestimation du poids fcetal et le poids
de naissance.
3. A la suite des therapeutiques prenatales, Pestriol
maternal plasmatique et urinaire, PHPL plasmatique et
la progesterone ont augmente de faqon significative
(Tab. II).
Mots-cles: Allylestrenol, determinations echographiques, estriol, fetus, HPL, progesterone, retard de croissance intra-
uterin.
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